The preclinical discovery and development of cariprazine for the treatment of schizophrenia

References

• Product information Vraylar® (cariprazine). Initial US approval. 2017. Reference ID: 4060067 - FDA.
   Google Scholar
• Summary of product characteristics Reagila® (cariprazine). WC500234924 EMA.
   Google Scholar
• Meszaros GP, Kapas M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopaminę D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol. 2007;217:S451–2.
   Google Scholar
• Kapas M, Meszaros GP, Yu B, et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol. 2008;1:433.
   Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opinion Drug Metab Toxicol. 2013;9:193–206.
   PubMed Web of Science ®Google Scholar
• Meszaros GP, Ágai-Csongor E, Kapas M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine. J Pharm Biomed Anal. 2008;48:388–397.
   PubMed Web of Science ®Google Scholar
• Kirschner N, Gemesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008;40:128–129.
   Web of Science ®Google Scholar
• Earley W, Durgam S, Lu K, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32:319–328.
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy f cariprazine in patients with acute exacerbaton of schizophrenia: a phase II, randomized clinical trial. Schizophrenia Res. 2014;152:450–457.
   PubMed Web of Science ®Google Scholar
• Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2015;35:367–373.
   PubMed Web of Science ®Google Scholar
• Ágai-Csongor E, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012;22:3437–3440.
   PubMed Web of Science ®Google Scholar
• Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partal agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328–340.
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopaminę D2 and serotonin 5-HT1A receptor properties. Psychopharmacology. 2011;216:451–473.
   PubMed Web of Science ®Google Scholar
• Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;668:355–365.
   PubMed Web of Science ®Google Scholar
• Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12:707–747.
   PubMed Web of Science ®Google Scholar
• De Deurwaerdère P. Cariprazine: new dopamine-biased agonist for neurpsychiatric disorders. Drug Today. 2016;52(2):1–14.
   Web of Science ®Google Scholar
• Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. 2011;218:579–587.
   PubMed Web of Science ®Google Scholar
• Kiss B, Horti F, Bobok A, et al. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor accupancy in vivo compared with other antipsychotics. Biol Psychiatry. 2012;71:40S.
   Web of Science ®Google Scholar
• Caccia S, Invernizzi RW, Nobili A, et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–328.
   PubMed Web of Science ®Google Scholar
• Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology. 2016;233:3503–3512.
   PubMed Web of Science ®Google Scholar
• Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999;288:774–781.
   PubMed Web of Science ®Google Scholar
• Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000;23:250–262.
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Dai J, O’Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325–339.
   PubMed Web of Science ®Google Scholar
• Assié MB, Ravailhe V, Faucillon V, et al. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther. 2005;315:265–272.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K, editor. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill Press; 2005. p. 461–500.
   Google Scholar
• Gyertyán I, Kiss B, Sághy K, et al. Caripazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and precognitive effects in rodents. Neurochem Int. 2011;59:925–935.
   PubMed Web of Science ®Google Scholar
• Choi YK, Adham N, Kiss B, et al. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectrum. 2014;19:268–277.
   PubMed Web of Science ®Google Scholar
• Choi YK, Adham N, Kiss B, et al. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectrum. 2017;22:484–494.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Pychopharmacology. 2008;198:103–111.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001;297:711–717.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 1997;78:985–996.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Yeghiayan SK, Baldessarini RJ, et al. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortcal D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997;17:186–196.
   PubMed Web of Science ®Google Scholar
• Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson’s disease. J Neural Transm. 1993;91:197–221.
   PubMed Web of Science ®Google Scholar
• Marcus MM, Nomikos GG, Svensson TH. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol. 1996;6:29–38.
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30:114–126.
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther Feb. 2013;30:102–113.
   PubMed Web of Science ®Google Scholar
• Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607–1619.
   PubMed Web of Science ®Google Scholar
• White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983;221:1054–1057.
   PubMed Web of Science ®Google Scholar
• Adham-Parangi N, Kiss B, Gyertyán I, et al. RGH-188, a potential antipsychotic with D3/D2 antagonist/partial agonist properties, exhibits an atypical antipsychotic profile in rats with respect to effect on spontaneously active dopamine neurons. Int J Neuropsychopharmacol. 2008;11(Suppl 1):P–07.69.
   Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology. 2002;161:263–270.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Pychopharmacol. 2010;24:341–348.
   PubMed Web of Science ®Google Scholar
• Francis PT, Pangalos JM, Pearson RC, et al. 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurons destroyed by intrastriatal volkensin. J Pharmacol Exp Ther. 1992;261:1273–1281.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Baldessarini J, Kula NS, et al. Long-term effects of olanzapine, risperidone, and quetiapine ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003;306:1145–1151.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009;63:413–420.
   PubMed Web of Science ®Google Scholar
• Spurney CF, Baca SM, Murray AM, et al. Differentia effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse. 1999;34:266–276.
   PubMed Web of Science ®Google Scholar
• Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev. 2000;31:302–312.
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol. 2001;41:237–260.
   PubMed Web of Science ®Google Scholar
• Gao X, Sakai K, Roberts RC, et al. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 2000;157:1141–1149.
   PubMed Web of Science ®Google Scholar
• Ariano M, Larson ER, Noblett KL, et al. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse. 1997;26:400–414.
   PubMed Web of Science ®Google Scholar
• Moore NA, Axton MS. The role of multiple dopamine receptors in apomorphine and N-n-propylnorapomorphine-induced climbing and hypothermia. Eur J Pharmcol. 1990;178:195–201.
   PubMed Web of Science ®Google Scholar
• Fabricius K, Helboe L, Fink-Jensen A, et al. Pharmacological characterization of social isolaton-induced hyperactivity. Psychopharmacology. 2010;215:257–266.
   PubMed Web of Science ®Google Scholar
• Fone KCF, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev. 2008;32:1087–1102.
   PubMed Web of Science ®Google Scholar
• McIntosh AL, Ballard TM, Steward LJ, et al. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology. 2013;228:31–42.
   PubMed Web of Science ®Google Scholar
• Watson DJG, King MV, Gyrtyán I, et al. The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26:208–224.
   PubMed Web of Science ®Google Scholar
• Castagne´ V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol. 2009;57:381–418.
   PubMedGoogle Scholar
• Leriche L, Schwartz JC, Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology. 2003;45:174–181.
   PubMed Web of Science ®Google Scholar
• Kapur S, Mizrahi, Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005;79:59–68.
   PubMed Web of Science ®Google Scholar
• Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006;31:1854–1863.
   PubMed Web of Science ®Google Scholar
• Neill JC, Barns S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128:419–432.
   PubMed Web of Science ®Google Scholar
• Hertzmann M, Reba RC, Kotlyarov EV. Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry. 1990;147:255–256.
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201–225.
   PubMed Web of Science ®Google Scholar
• Neill JC, Graysoon B, Kiss B, et al. Effects of cariprazine, a novel antipsychotic, on cognitive and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26:3–14.
   PubMed Web of Science ®Google Scholar
• Barnes SA, Sawiak SJ, Caprioli D, et al. Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol. 2014;18:1–12.
   Web of Science ®Google Scholar
• Bubenikova-Valesova V, Horacek J, Vrajova M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32:1014–1023.
   PubMed Web of Science ®Google Scholar
• Mouri A, Noda Y, Enomoto T, et al. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007;51:173–184.
   PubMed Web of Science ®Google Scholar
• McIntosh AL, Ballard TM, Steward LJ, et al. Clozapine reverses recognition memory but not social interaction deficits in a “dual-hit” rat model of schizophrenia. Schizophr Res. 2012;136:S282.
   Web of Science ®Google Scholar
• Goosens KA, Maren S. Contextual and auditory fear conditioning ae mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn Mem. 2001;8:148–155.
   PubMed Web of Science ®Google Scholar
• Cools R, Brouwer WH, de Jong R, et al. Flexibility, inhibition, and planning: frontal dysfunctioning in schizophrenia. Brain Cogn. 2000;43:108–112.
   PubMed Web of Science ®Google Scholar
• Jacobs R, Anderson V. Planning and problem solving skills following focal frontal brain lesions in childhood: analysis using the Tower of London. Child Neuropsychol. 2002;8:93–106.
   PubMed Web of Science ®Google Scholar
• Shamay-Tsoory SG, Tomer R, Goldsher D, et al. Impairment in cognitive and affective empathy in patients with brain lesions: anatomical and cognitive correlates. J Clin Exp Neuropsychol. 2004;26:1113–1127.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Harvey PD. Treatment of cognitive deficits in schizophrenia. Curr Opin Investig. 2006;7:608–613.
   PubMed Web of Science ®Google Scholar
• Elliott R, McKenna PJ, Robbins TW, et al. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med. 1995;25:619–630.
   PubMed Web of Science ®Google Scholar
• Leeson VC, Robbins TW, Matheson E, et al. Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry. 2009;66:586–593.
   PubMed Web of Science ®Google Scholar
• Pantelis C, Barber FZ, Barnes TR, et al. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res. 1999;37:251–270.
   PubMed Web of Science ®Google Scholar
• Bissonette GB, Powell EM. Reversal learning and attentional set-shifting in Mice. Neuropharmacology. 2012;62:1168–1174.
   PubMed Web of Science ®Google Scholar
• Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology. 2013;226:91–100.
   PubMed Web of Science ®Google Scholar
• Richmond MA, Yee BK, Pouzet B, et al. Dissociating context and space within the hippocampus: effects of complete, dorsal, and ventral excitotoxic hippocampal lesions on conditioned freezing and spatial learning. Behav Neurosci. 1999;113:1189–1203.
   PubMed Web of Science ®Google Scholar
• Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35:68–77.
   PubMed Web of Science ®Google Scholar
• Willner P. The chronic mild stress model of depression: history, evaluation and usage. Neurobiol Stress. 2017;6:7–93.
   Web of Science ®Google Scholar
• Papp M. Models of affective illness: chronic mild stress in the rat. Curr Protoc Pharmacol. 2012.;57:5.9.1–5.9.11.
   PubMedGoogle Scholar
• Papp M, Gruca P, Lasoń-Tyburkiewicz, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567–574.
   PubMed Web of Science ®Google Scholar
• Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20:78–96.
   Web of Science ®Google Scholar
• Bersani G, Pesaresi L, Orlandi V, et al. Atypical antipsychotics and polydipsia: a cause or a treatment? Hum Psychopharmacol. 2007;22:103–107.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Mannesse CK, Jansen PA, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf. 2010;33:101–114.
   PubMed Web of Science ®Google Scholar
• Herman L, Hougland T, El-Mallakh RS. Mimicking human bipolar ion dysregulation models mania in rats. Neurosci Biobehav Rev. 2007;31:874–881.
   PubMed Web of Science ®Google Scholar
• Gao Y, Peterson S, Masri B, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2014;3:1–10.
   Web of Science ®Google Scholar
• Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: a meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–389.
   PubMed Web of Science ®Google Scholar
• Román V, Gyertyán I, Sághy K, et al. Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology. 2013;226:285–293.
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine for the treatment of schizophrenia: a review of this dopamine D3-preferring D3/D2 receptor partial agonist. Clin Schizophr Relat Psychoses. 2016;10(2):109–119.
   Google Scholar
• Stahl SM. Mechanism of action of cariprazine. CNS Spectrums. 2016;21(2):123–127.
   PubMed Web of Science ®Google Scholar
• Auclair AL, Cathala A, Sarrazin F, et al. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem. 2010;114(5):1323–1332.
   PubMed Web of Science ®Google Scholar
• Pitychoutis P, Belmer A, Moutkine I, et al. Mice lacking the serotonin Htr2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype. Neuropsychopharmacology. 2015;40(12):2764–2773.
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargós-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252–265.
   PubMed Web of Science ®Google Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389:1103–1113.
   PubMed Web of Science ®Google Scholar
• Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32:309–318.
   PubMed Web of Science ®Google Scholar
• Scarff JR. The prospects of cariprazine in the treatment of schizophrenia. Ther Adv Psychopharmacol. 2017;7:237–239.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77:371–378.
   PubMed Web of Science ®Google Scholar